<DOC>
	<DOCNO>NCT01056523</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose ribavirin , give combination low-dose ara-C determine safe well-tolerated patient acute myeloid leukemia .</brief_summary>
	<brief_title>Use Ribavirin Low Dose Ara-C Treat Acute Myeloid Leukemia</brief_title>
	<detailed_description>Primary Objectives In Phase I portion study , determine maximum tolerate dose recommended phase II dose ( RP2D ) ribavirin low-dose ara-C . The primary objective Phase II portion study determine overall response rate , include complete remission ( CR ) , complete remission incomplete blood count recovery ( CRi ) , partial remission ( PR ) blast response ( BR ) , therapy ribavirin low dose ara-C RP2D . STUDY DESIGN AND DURATION This multicentre , open-label , single arm Phase I/II study oral ribavirin low-dose ara-C patient AML M4/M5 AML high expression eIF4E , relapse refractory disease , suitable candidate induction chemotherapy . This study determine recommend phase II dose evaluate efficacy . Correlative study include assess relevant molecular target .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>The following patient acute myeloid leukemia ( AML ) eligible : De novo AML M4 M5 FAB subtype high eIF4E . Secondary AML myelodysplastic syndrome ( MDS ) myeloproliferative disorder ( chronic myelogenous leukemia ) , M4 M5 FAB subtype high eIF4E . Therapyrelated AML M4 M5 FAB subtype high eIF4E . CML blast crisis fail imatinib least one tyrosine kinase inhibitor . All patient must fail primary therapy ( define two induction chemotherapy ) , relapse , suitable candidate intensive induction chemotherapy . Patients dry aspirate extramedullary disease eligible study pretreatment marrow tissue biopsy demonstrate AML M4 M5 subtype high eIF4E expression . ECOG performance status 0 , 1 , 2 3 . Life expectancy &gt; 4 week . Age &gt; 18 year . Female patient childbearing potential must negative serum ( betaHCG ) pregnancy test within 14 day start protocol must breastfeed . Men woman childbearing potential must agree use effective mean contraception throughout study least 30 day completion protocol . Adequate renal hepatic function : serum creatinine &lt; 1.5 x ULN ; AST ALT &lt; 2.5 x ULN ( &lt; 5 x ULN liver involvement leukemia ) ; serum bilirubin &lt; 1.5 x ULN . Provide write consent investigational nature , study design , risk benefit study explain . Accessible treatment follow . Uncontrolled central nervous system involvement AML . Active cardiovascular disease define New York Heart Association ( NYHA ) class IIIIV categorization . Intercurrent illness medical condition preclude safe administration plan protocol treatment require followup . Received previous therapy AML within 28 day prior study entry . Hydrea permit treatment leukocytosis must stop within 7 day start low dose araC ribavirin . Female patient pregnant breastfeeding . Concurrent treatment anticancer therapy . Known infection HIV . History malignancy . Subjects diseasefree 2 year subject history completely resect nonmelanoma skin cancer successfully treat situ carcinoma eligible . FAB AML M1 , 2 , 6 , 7 exclude high eIF4E expression . AML M3 always exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>AML</keyword>
</DOC>